These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.
    Author: Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G.
    Journal: Fertil Steril; 2009 Sep; 92(3):1045-1052. PubMed ID: 19635616.
    Abstract:
    OBJECTIVE: To evaluate the efficacy of the tissue-selective estrogen complex, bazedoxifene/conjugated estrogens (BZA/CE), for postmenopausal osteoporosis prevention. DESIGN: Multicenter, randomized, double-blind, placebo- and active-controlled, phase 3 trial (Selective estrogen Menopause And Response to Therapy [SMART]-1). SETTING: Outpatient clinical study. PATIENT(S): Women (n = 3,397) more than 5 years and 1-5 years postmenopause were enrolled in the Osteoporosis Prevention I and II Substudies, respectively. INTERVENTION(S): Single tablets of BZA (10, 20, or 40 mg) each with CE (0.625 or 0.45 mg), raloxifene (60 mg), or a placebo taken daily for 2 years. MAIN OUTCOME MEASURE(S): The primary outcome for both substudies was change in bone mineral density of the lumbar spine; bone mineral density was also measured at the hip. RESULT(S): In both substudies, bone mineral density increased significantly more with all BZA/CE doses compared with placebo at the lumbar spine and total hip, and for most BZA/CE doses compared with raloxifene at the lumbar spine. Osteocalcin and N-telopeptide significantly decreased with all BZA/CE doses vs. placebo and most BZA/CE doses vs. raloxifene. CONCLUSION(S): BZA/CE combinations decreased bone turnover and bone loss in postmenopausal women at increased risk for osteoporosis.
    [Abstract] [Full Text] [Related] [New Search]